ABSTRACT
While asthma is increasingly recognized as an inflammatory disease, there is little question that residual bronchospasm must also be treated to provide a comfortable and productive existence for the patient. ~2 agonists are the principal bronchodilators, and, at times of crisis, indispensable. Yet, despite continuing improvements, ~2 agonists remain controversial. Asthma morbidity is increasing, and some are convinced that regular use of inhaled ~2 agonists is detrimental (1).
